Small-diameter titanium grade IV and titanium-zirconium implants in edentulous mandibles: five-year results from a double-blind, randomized controlled trial

Frauke Müller1*, Bilal Al-Nawas2, Stefano Storelli3, Marc Quirynen4, Stefan Hicklin5, Jose Castro-Laza6, Renzo Bassetti7, Martin Schimmel1,5 and On behalf of the Roxolid Study Group

Abstract

Background: The aim of this study was to compare the 5-year survival and success rates of 3.3 mm dental implants either made from titanium-zirconium (TiZr) alloy or from Grade IV titanium (Ti Grade IV) in mandibular implant-based removable overdentures.

Methods: The core study had a follow-up period of 36 months and was designed as a randomized, controlled, double-blind, split-mouth multicenter clinical trial. Patients with edentulous mandibles received two Straumann Bone Level implants (diameter 3.3 mm, SLActive®), one of TiZr (test) and one of Ti Grade IV (control), in the interforaminal region. This follow-up study recruited patients from the core study and evaluated the plaque and sulcus bleeding indices, radiographic crestal bone level, as well as implant survival and success 60 months after implant placement.

Results: Of the 91 patients who initially received implants, 75 completed the 36 month follow-up and 49 were available for the 60 month examination. Two patients were excluded so that a total of 47 patients with an average age of 72 ± 8 years were analysed. The characteristics and 36-month performance of the present study cohort did not differ from the non-included initial participants (p > 0.05). In the period since the 36-month follow-up examination, no implant was lost. The cumulative implant survival rate was 98.9 % for the TiZr group and 97.8 % for the Ti Grade IV group. Crestal bone level changes at 60 months were not different in the test and control group (TiZr −0.60 ± 0.69 mm and Ti Grade IV −0.61 ± 0.83 mm; p = 0.96). The cumulative implant success rate after 60 months was 95.8 and 92.6 % for TiZr and Ti Grade IV, respectively.

Conclusions: After 60 months, the positive outcomes of the 36 month results for TiZr and Ti Grade IV implants were confirmed, with no significant differences with regard to crestal bone level change, clinical parameters and survival or success rates. TiZr implants performed equally well compared to conventional Ti Grade IV 3.3 mm diameter-reduced implants for mandibular removable overdentures.

Trial registration: Registered on www.clinicaltrials.gov: NCT01878331

Keywords: Overdentures, TiZr, Ti Grade IV, SLActive, Split-mouth, Roxolid
Background

Despite the progress in restorative techniques and preventive measures, tooth loss has still a high prevalence in the older population, yet tends to occur later in life [1–3]. This presents the dental profession with more edentulous patients, where physiological ageing and multimorbidity often dominate the dental treatment planning [4]. Age-adapted treatment planning requires easy to manage and reversible treatment concepts which take into consideration a reduced hand grip strength, dexterity, vision and tactile sensitivity of the patient. Prospective planning is required in view of a potential future functional decline which may render the patient dependent for the activities of daily living. The implant mandibular overdenture with two interforaminal implants presents a multitude of functional and psychosocial improvements for the edentulous patient when compared to a conventional complete denture, which often falls short in fully restoring impaired oral function after tooth loss [5, 6]. Encouraged by long-term success of implant-overdentures, the indications of endosseous implants are more extended to clinically challenging situations in terms of available bone volume for implant anchorage as well as compromised general health conditions [7, 8]. Progress in the implant surfaces have allowed for shorter healing times and improved osseointegration [9]. New alloys have been developed with improved mechanical properties which allow diameter-reduced implants being inserted even in clinically unfavourable anatomical conditions and thus further extend the indications for implant restorations [10]. It is important that implants are designed to have the possibility for a “back-off” strategy if a less retentive and sophisticated restoration is needed in end of life care. In this aspect, two-piece implants present the advantage that the abutment can be removed and exchanged for a lower retention abutment or even a healing cap when functional decline renders denture management or denture wearing difficult. As neuroplasticity is diminished in old age, treatment planning includes avoiding comprehensive changes of dental restorations in very old age, thus preferring versatile and transformable prosthodontic restorations.

Titanium is considered the “gold standard” for dental implants due to its corrosion resistance and biocompatibility [11], but titanium alloys containing zirconium show even better tensile and fatigue strength than pure titanium [12]. For increasing the strength for small-diameter two-piece implants, titanium-zirconium (TiZr) alloy (Roxolid®; Institut Straumann AG, Basel, Switzerland) implants with the SLActive® surface have been introduced. 36 months non-inferiority of Roxolid® implants was reported for mandibular overdentures in a multi-center RCT [13, 14]. The present study aims to confirm the safety and long term clinical performance in terms of crestal bone level change, physical stability and peri-implant health of Roxolid® implants after 60 months in the previously reported patient cohort provided with two-implant-based overdentures.

Methods

This study was designed as prospective 5 to 10 years follow-up of a randomized, controlled, double-blind, split-mouth, multi-centre clinical trial that came to its end after 36 months (core study). The materials and methods of the core study have been published previously [13, 14] and will be briefly summarized here. The core study has been conducted at eight sites in five countries (Belgium, Germany, Italy, the Netherlands and Switzerland). The follow-up study was conducted at 6 sites in 4 countries (Belgium, Germany, Italy and Switzerland). The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice (ISO 14155:2011) and approved by the Independent Ethics Committees of the coordinating investigator and all study sites. All participating patients gave their written informed consent. The study was registered at www.clinicaltrials.gov (registration no. NCT01878331 [15]).

Patients and implants

Patients who had completed the core study were invited to participate in the follow-up study to collect long-term data, 5 and 10 years after implant placement. The patients were selected according to predefined inclusion and exclusion criteria. The inclusion criteria were:

- Treatment in the core study,
- completed 36 month visit of the core study,
- informed and written consent and
- commitment to participate in the study over the entire study duration.

The exclusion criteria were:

- Physical handicaps interfering with the ability to perform adequate oral hygiene,
- failure to attend follow-up visits and
- use of any investigational drug or device during the study period.

During the core study the patients were selected according to predefined inclusion and exclusion criteria. The inclusion criteria were: edentulous mandible, age ≥18 years, last tooth extraction >8 weeks prior to surgery, sufficient bone height of at least 9 mm and bone width for a 3.3 mm diameter implant installation without simultaneous bone augmentation, as well as an edentulous opposing dentition with an implant born or conventional denture or a natural or restored dentition.
The exclusion criteria essentially referred to various medical conditions and can be consulted in the first publication of the core study [13]. All patients had presented with an edentulous mandible and had received two Straumann Bone Level implants (Institut Straumann AG, Basel, Switzerland) in the interferominal region, randomly allocated to one side in a double-blind, split-mouth design. Both implants had exactly the same design with a diameter of 3.3 mm and a SLActive surface, the test implant was fabricated from titanium-zirconium (TiZr) and the control implant from Grade IV titanium (Ti Grade IV).

Clinical procedure
In the core study, surgery had been performed under local anaesthesia following a standard surgical procedure. Implants of 8, 10, 12 and 14 mm length had been inserted and healing abutments had been installed to allow for trans-mucosal healing. Sutures had been removed 1 to 2 weeks after surgery and the healing abutments had been replaced by Locator abutments (Zest Anchors LLC, Escondido, CA, USA) 6 to 8 weeks after implant placement. Within two weeks following abutment connection the removable dentures were relined to incorporate the female Locator parts. No metal framework was placed. The patients had attended follow-up visits at 6, 12, 24 and 36 months. Patients from 6 centres who consented for the follow-up study were recalled for the 60 month clinical visit. An additional follow-up is planned for 10 years after implant placement.

Implant survival and success
Implants still in place 60 months after surgery were counted as surviving implants. Adapted from the Buser criteria, implant success was defined as follows: The possibility for restoration, the absence of persistent patient complaints (pain, foreign body sensation and/or dysesthesia), the absence of recurrent peri-implant infection with suppuration, the absence of implant mobility and the absence of continuous radiolucency around the implant [16].

Peri-implant bone level
Standardized panoramic radiographs had been taken at baseline and 6, 12, 24, 36 and 60 months after implant placement (Fig. 1). Film-based images were digitized via video camera, light box and image analysis program [17, 18] and digital images were analyzed using ImageJ 1.33 open software (National Institutes of Health, Bethesda, MD, USA). The analysis of all images was performed by an independent expert.

The known implant length had been used as reference for the analysis. The reference line for the bone level measurements was the implant chamfer 0.2 mm above the implant shoulder. The bone level was defined as distance between the reference point and the first bone-to-implant contact (Fig. 2). The mean value from mesial and distal measurements was used for the evaluation. The bone level change was calculated as a function of the baseline level at implant placement.

Soft tissue assessment
Soft tissue assessment had been performed at prosthesis placement and 6, 12, 24, 36 and 60 months after implant placement by calibrated operators. Modified Plaque Index (mPI) and the modified Sulcus Bleeding Index (mSBI) according to Mombelli were recorded for the lingual, buccal, mesial and distal sites of the implant [19].

Safety assessment
Patient safety evaluation included reporting of complications, adverse events (AEs), serious adverse events (SAEs) and device deficiencies. AEs and SAEs were assessed for their relation to the study device and severity.

Statistical analysis
Efficacy analysis was performed for crestal bone level change, implant survival and success and soft tissue parameters up to 60 months after implant placement based on the “per protocol” (PP) data set. Comparisons between the test and the control group were based on the corresponding 95 % confidence intervals. Changes in crestal bone levels have been compared by t-tests between the treatment groups, the p-values are of descriptive nature. Continuous data are presented as mean.

Fig. 1 Radiograph showing test and control implant in the interferominal region. The analysis was performed by an independent investigator using ImageJ software.
values (± standard deviation, SD). For the analysis of
crestal bone level changes presented here missing data
were not imputed. Differences in the mPI and the mSBI
were evaluated by the Wilcoxon Rank Sum test. Kaplan-
Meier analysis was used to evaluate implant success and
survival and the distributions were compared by log-
rank tests. The “safety data” encloses all enrolled pa-
tients, who received a study device during the core
study. The “intention to treat” (ITT) population com-
prises all enrolled subjects regardless of any protocol
deviation and/or premature termination. The PP popu-
lation comprises all enrolled patients in whom no
major protocol deviation was observed.

Results
Patients
Ninety-one patients were enrolled in the core study and
75 patients completed the 36 month visit. During this
period, 11 patients were lost to follow up, one withdrew
consent, one had an adverse event unrelated to the study
treatment and three study participants died. Following
the 36 month examination, 26 patients were either lost
for follow-up or were not eligible for various reasons:
One patient was the only patient treated in one centre
and it seemed unreasonable to request ethical permis-
son. Another centre did not receive the clearance from
the Ethics Committee for the continuation of the study
in time; hence further nine patients were not eligible for
participation. Finally, 49 patients from the core study
were available at the 60 month visit and consented to
participate in the follow-up study (Fig. 3). The patient
recruitment for the follow-up period started in June
2013 and the last 60 month visit was performed in
January 2014.

All 49 patients were eligible for the safety evaluation.
One patient was excluded from the ITT population be-
cause of unknown implant allocation during the core
study (n = 48, ITT population). Furthermore, one patient
could not be analysed according to the PP population,
because one of the two implants was lost and replaced
during the core study (n = 47, PP population). For many
patients time window deviations were observed and cat-
egorized as “minor protocol deviations” without further
consequences for the data analysis.

The mean age of the PP population was 72 ± 8 years at
the 60 month follow-up (range 54 – 92 years). The pa-
tient demographic data are presented in Table 1. The
majority of patients (87.2 %) suffered from clinically rele-
vant diseases; among the most frequent ones were
hypertension and hyperlipidaemia.

The primary efficacy variable is implant survival
assessed 10 years after implant placement, but the study
design includes the assessment of various secondary pa-
rameters after 5 and 10 years.

Implant survival and success
During the observation period of the follow-up study,
between 36 and 60 months after implant placement, no
implants were lost. However, three implants had been
lost during the core study within the first 12 months
after implant placement, one in the test group (TiZr)
and two in the control group (Ti Grade IV). Kaplan-

Fig. 2 Illustration of the bone level measurements. (1) Chamfer to first implant-to-bone contact, mesial (2) Chamfer to first implant-to-bone contact, distal (3) Length of implant
Meier curves show that the probability of implant survival is declining to 98.9 % for the TiZr group and to 97.8 % for the Ti Grade IV group within the first year after implant placement and remains stable at this level for up to 60 months. There were no significant differences between the two groups ($p = 0.56$). Considering the 26 patients, who were either "lost to follow-up" after completion of the core study or not eligible for participation, as failures, a worst case scenario would result in an implant survival of 53.8 %.

During the core study one implant of each, the test and the control group had been classified as “not successful” due to peri-implant infection and suppuration. In addition, at the 60 month visit one patient showed a peri-implant infection around the TiZr implant. Further, two Ti Grade IV implants were considered not successful due to continuous radiolucency around the implants. Therefore, the cumulative implant success rates (Fig. 4) were 95.8 % and 92.6 % for TiZr and Ti Grade IV, respectively (Kaplan Meier curves; failed implants were also counted as “not successful”; $p = 0.47$).

**Bone level change**

There were no significant differences in crestal bone level changes between the TiZr and the Ti Grade IV group, assessed 60 months after implant placement ($p = 0.96$). The mean change in the TiZr group was $-0.60 \pm 0.69$ mm and in the Ti Grade IV group $-0.61 \pm 0.83$ mm, ranging from $-3.57$ to 0.16 mm and from $-3.65$ to 0.44 mm, respectively. The majority of implant sites showed crestal bone loss between 0 and 1.0 mm or crestal bone gain (Fig. 5). Crestal bone level changes were more pronounced in the first years after implant placement.

**Table 1** Demographic data of the study population

| Gender       | Number | Percent |
|--------------|--------|---------|
| Male         | 24     | 51.1    |
| Female       | 23     | 48.9    |
| Smoking status |       |         |
| Non-smoker   | 31     | 66.0    |
| Past-smoker$^a$ | 16     | 34.0    |
| Current clinically relevant disease |       |         |
| Yes$^b$      | 41     | 87.2    |
| No           | 6      | 12.8    |

Demographic patient data, 60 months after implant placement (PP population, $n = 47$). $^a$ i.e. $> 10$ cigarettes/day; $^b$ most frequently hypertension and hypercholesterolemia.
Fig. 4 Kaplan-Meier analysis of implant survival and success. a) Implant survival and b) success from implant placement to 60 months. Patients lost to follow-up during or after completion of the core study (0–36 months) were censored. Scaling of the Y-axes 0.92 to 1.00.

Fig. 5 Categorized changes in peri-implant bone level 60 months after implant placement. Implants were categorized according to crestal bone level change (PP population, n = 47, some radiographs were impossible to analyse).
placement (Fig. 6). A sensitivity analysis was performed for the core study (12, 24 and 36 months) confirming that there were no significant differences between the original patient population and the population of this follow-up study with regard to crestal bone level changes ($p = 0.44, 0.41$ and $0.61 \ (\text{Ti Grade IV})$, respectively). Soft tissue and safety assessments

After 60 months no significant differences in mPI and mSBI were determined between the patients of the TiZr and the Ti Grade IV group ($p = 0.23$ and $p = 0.77$, respectively). Most of the patients showed an mPI score 0 or 1 and the same results were observed for the mSBI (Table 2).

Four of the 49 patients (8.2 %) experienced an AE during the observational period from 36 to 60 months. In accordance with the assessment of implant success, two patients presented with radiolucency around the implant and one patient with peri-implant infection, classified as AEs related to the study device. Another AE, a denture related ulcer, was not related to the implant. None of the patients experienced an SAE between 36 and 60 months after implant placement.

Table 2 Plaque index and sulcus bleeding indices after 60 months

|             | Plaque Index (mPI) | Sulcus Bleeding Index (mSBI) |
|-------------|--------------------|------------------------------|
|             | TiZr %             | Ti Grade IV %                |
| Score 0     | 59.6               | 68.6                         |
| Score 1     | 15.4               | 16.0                         |
| Score 2     | 16.5               | 8.5                          |
| Score 3     | 8.5                | 7.4                          |

Modified Plaque Index and modified Sulcus Bleeding Index according to Mombelli et al. [19], 60 months after implant placement ($p = 0.23 \ (\text{mPI}), p = 0.77 \ (\text{mSBI})$, PP population, $n = 47$)

Discussion

This study was designed as a prospective, randomized, double-blind and split-mouth clinical trial, where dental implants made of TiZr alloy were compared to implants made of Ti Grade IV. Both types of implants had a SLA-active surface. After an observation period of 60 months, no significant differences in crestal bone level change, clinical parameters or survival and success rates were found between the groups. The outcomes seen at 12 as well as 36 months continued until 60 months, indicating that TiZr implants in this clinical setting were comparable to Ti Grade IV implants.

Long-term observations are highly relevant when recommending a medical device for clinical use, even more so for elderly patients, where prosthodontic restorations should be designed for long-term survival, as renewal of prostheses might become difficult with increasing frailty and multimorbidity. Adjustments which may become necessary to adapt the prosthodontic restoration to functional decline should rather be performed by a simple alteration of the denture to minimize the challenges to an elderly person's neuroplasticity and capacity of adaptation. Complications or failures in late life can be minimized when using only well documented and high quality materials for dental restorations. Biological complications may still occur, as the overall risk of implant failure seems influenced by biological parameters like history of periodontal disease or residual periodontal pockets [20–22]. Patient behaviour such as smoking [23, 24] unfavourable oral hygiene [25] or the absence of an adequate peri-implant width of keratinized and attached mucosa [26, 27] may also play a role. Technical aspects such as implant design and surface may also largely vary the clinical outcome, as was recently demonstrated in a large-scale industry independent study on implant survival [28]. In this study the mentioned risk factors were confirmed, and in addition, implant length and implant brand were identified as relevant factors for implant survival and success.

The present data confirm that Roxolid® implants were comparable to the traditional Grade IV titanium alloy in 3.3 mm diameter implants for an implant-supported mandibular overdenture over a 60 months period. This confirmation is of particular importance with regard to the above mentioned concern about safety and quality of implant materials in pre-elderly and elderly patients. The peri-implant bone loss, modified Plaque Index, modified Sulcus Bleeding Index as well as implant success and survival are not statistically different between the two implant materials. One of the strengths of this study is the split-mouth design, which provides an identical biological environment to the test and control implant. Another strength is the use of 3.3 mm diameter implants in a region, where the bone volume might
often, but not always be available for larger diameter implants. Even the right- or left handedness of a patient or the preferred chewing side may not have influenced the results, as the side-attrition of the test and control group was randomized. However, any clinical study has inherent inconsistencies, as one patient may vary from the other in a multitude of aspects. A further substantial shortcoming is that not all of the 92 patients who originally received implants were available for all follow-up visits. The core study was planned for 36 months, and ethical permission and insurance had expired after this follow-up period and renewal was necessary. One centre had only one participant recruited, and it seemed unreasonable to undergo the effort of study submission to the Ethics Committee for this single case. A further centre did not obtain ethical approval in time. A total of 26 patients was lost for recruitment for the present study. A worst-case survival rate was therefore calculated at 53.8 %. However, knowing that 10 patients were not included for formal reasons, and taking into account that the included patients did not differ statistically from the not-included participants from the core study at baseline as well as at 12, 24 and 36 month follow-up, it seems reasonable to assume that this worst-case scenario is unrealistic. The crestal bone level changes reported in the present study are within the range reported in the literature for similar clinical indications. A recent meta-analysis on marginal bone level changes at dental implants after an observation period of 60 months concludes that the annual bone loss is below or much below what hitherto has been reported [29]. The marginal bone loss noted in the present patient cohort after 60 months was −0.60 ± 0.69 mm for the TiZr group and −0.61 ± 0.83 mm in the Ti Grade IV group, respectively. The reported bone level changes after 60 months are in between the one reported by Laurell and Lundgren for the Straumann Dental Implant System (0.48 mm (95 % CI −0.598, −0.360) and the Bränemark System with 0.75 mm (95 % CI −0.802, −0.693). When comparing these results with the ones from the meta-analysis, one has to keep in mind that both, elderly and edentulous patients are at particular risk for reduced oral hygiene measures. Around one third of this study’s patient cohort did present with modified Plaque Index and modified Sulcus Bleeding Index scores above zero. However, little is known on the impact of biofilm on the peri-implant bone level [30], especially for elderly patients with an aged immune system. The relation between peri-implantitis and oral hygiene will be of increasing importance for the dental profession, as a growing number of patients with implants will age, hence poor oral hygiene seems pre-programmed.

The benefits of implant overdentures for edentulous patients are well documented and the cost-effectiveness of this treatment protocol has been demonstrated [5, 6, 31]. Compared to conventional dentures, the chewing efficiency may be significantly improved, given that new implant-supported removable overdentures are manufactured [32]. The chewing muscles seem more trained due to the improved chewing performance and after stabilizing a lower denture by means of implants the muscle bulk can be re-gained, even in very old adults [33, 34]. A similar effect of training and re-training was shown also for the leg muscles in a geriatric context [35]. Further improvements of overdentures compared to conventional complete dentures comprise denture satisfaction and Oral Health Related Quality of Life [36], although these outcome measures are complex and may vary between cultures and personalities [37]. Elderly persons are in general less demanding concerning an improvement of their denture performance [38, 39], yet do in general appreciate an improvement of their chewing performance [40–42]. Nevertheless, around one third of edentulous patients reject implant insertion because they object the surgical intervention [43]. Low-diameter implants may not only have a positive effect on the preservation of the residual alveolar ridge and therefore be biologically favourable in certain clinical situations. They may also avoid invasive bone augmentation procedures [44] whereby patient’s morbidity as well as treatment costs and time can be reduced significantly [10] and the smaller the intervention, the more likely is the acceptance in edentulous patients.

Conclusion
In conclusion it can be stated that the TiZr alloy (Roxolid®) implants provide a long-term safe and reliable alternative to the available portfolio of dental implants, traditionally manufactured from Ti Grade IV. The improved mechanical properties of TiZr may extend the indications in implant therapy to more challenging clinical situations and allow promoting a minimal invasive treatment approach which is particularly suitable for elderly patients.

Abbreviations
AE: Adverse event; ITT: Intent to treat; mPI: Modified plaque index; mSBI: Modified sulcus bleeding index; PP: Per protocol; SAE: Serious adverse event; SD: Standard deviation; TiZr: Titanium-zirconium; Ti Grade IV: Titanium grade IV.

Competing interests
The authors have no conflicts of interest to declare. A moderate per capita remuneration was received by the institution per completed CRF.

Authors’ contributions
FM and MS prepared the manuscript. All authors contributed to this clinical trial, i.e. study design, study conduct, data collection and review of the manuscript. All authors approved the manuscript prior to submission.

Acknowledgements
The trial was sponsored by Institut Straumann AG, Basel, Switzerland. Roxolid Study Group: Bilal Al-Nawas (Johannes-Gutenberg University, Mainz, Germany); Carina Aschenbrenner (University of Regensburg Clinic, Germany); Carina Aschenbrenner (University of Regensburg Clinic, Germany); Carina Aschenbrenner (University of Regensburg Clinic, Germany); Carina Aschenbrenner (University of Regensburg Clinic, Germany).
Regensburg, Germany); Renzo Bassetti (Cantonal Hospital Lucerne, Lucerne, Switzerland); Jose Castro-Laza (University of Regensburg Clinic, Regensburg, Germany); Gitte Cuyx (Catholic University Leuven, Leuven, Belgium); Joke Dyck (Catholic University Leuven, Leuven, Belgium); Henny JA Meijer (University Medical Center Groningen, University of Groningen, Groningen, the Netherlands); Kraike Müller (University of Geneva, Geneva, Switzerland); Ignacio Naert (Catholic University Leuven, Leuven, Belgium); Alessandro Perucchi (Cantonal Hospital Lucerne, Lucerne, Switzerland); Marc Quinney (Catholic University Leuven, Leuven, Belgium); Amir Razavi (Cantonal Hospital Lucerne, Lucerne, Switzerland); Torsten Reichert (University of Regensburg Clinic, Regensburg, Germany); Eugenio Romeo (University of Milan Dental Clinic, Milan, Italy); Martin Schimmel (University of Geneva, Geneva, Switzerland); Keyvan Sagheb (Johannes-Gutenberg University, Mainz, Germany); Stefano Storelli (University of Milan Dental Clinic, Milan, Italy); Wilfried Wagner (Johannes-Gutenberg University, Mainz, Germany); Daniel Wismeijer (Academic Center for Dentistry Amsterdam, Amsterdam, the Netherlands); Cornelia Winkler (University of Regensburg Clinic, Regensburg, Germany).

Author details
1 Division of Gerodontology and Removable Prosthodontics, University of Geneva, Geneva, Switzerland. 2 Johannes-Gutenberg University Mainz, Mainz, Germany. 3 University of Milan, Dental Clinic, San Paolo Hospital, Milan, Italy. 4 School of Dentistry, Catholic University Leuven, Leuven, Belgium. 5 University of Bern, School of Dental Medicine, Bern, Switzerland. 6 University of Regensburg Clinic, Regensburg, Germany. 7 Cantonal Hospital Lucerne Clinic for Oral and Maxillofacial Surgery, Lucerne, Switzerland.

Received: 17 May 2015 Accepted: 5 October 2015

References
1. Hughson A, Koch G, Goethberg C, Helkimo AN, Lundin SA, Norderyd O, et al. Oral health of adults aged 3–80 years in Jonköping, Sweden during 30 years (1973–2003). II. Review of clinical and radiographic findings. Swed Dent J. 2005;29(4):139–55.
2. Mojon P. The world without teeth: Demographic Trends. In: Feine J, Carlsson GE, editors. Implant Overdentures, the Standard of Care for Edentulous Patients. Chicago: Quintessence; 2003. p. 3–14.
3. Müller F, Naharro M, Carlsson GE. What are the prevalence and incidence of tooth loss in the adult and elderly population in Europe? Clin Oral Implants Res. 2007;18 Suppl 3:2–14.
4. MacEntee MI, Müller F, Wyatt CC. Oral Healthcare and The Frail Elder: A Clinical Perspective. Ames: Wiley-Blackwell; 2011.
5. Feine JS, Carlson GE, Awad MA, Chahade A, Duncan WJ, Gizani S, et al. The McGill consensus statement on overdentures. Mandibular two-implant overdentures as first choice standard of care for edentulous patients. Gerodontology. 2002;19(1):3–4.
6. Thomason JM, Feine J, Eley C, Moynihan P, Muller F, Naert I, et al. Mandibular two implant-supported overdentures as the first choice standard of care for edentulous patients—the York Consensus Statement. Br Dent J. 2009;207(4):185–6.
7. Andreotti M, Att W, Strub JP. Prosthodontic complications with implant overdentures: a systematic literature review. Int J Prosthodont. 2010;23(1):195–203.
8. Enghoff I, Ortoft A, Jernt T. Fixed implant-supported prostheses in elderly patients: a 5-year retrospective study of 133 edentulous patients older than 79 years. Clin Implant Dent Relat Res. 2004;6(4):190–8.
9. Schimmel M, Sinivasan M, Hermann FR, Muller F. Loading protocols for implant-supported overdentures in the edentulous jaw: a systematic review and meta-analysis. Int J Oral Maxillofac Implants. 2014;29(Suppl):271–86.
10. Sordoni K, Mudhattan A, Esfandari S, Feine J. How successful are small-diameter implants? A literature review. Clin Oral Implants Res. 2011;22(12):1151–25.
11. Ikashira Y, Toyoda K, Kobayashi E. Improved Biocompatibility of Titanium-Zirconium (Ti-Zr) Alloy: Tissue Reaction and Sensitization to Ti-Zr Alloy Compared with Pure Ti and Zr in Rat Implantation Study. Mater Trans. 2005;46:260–7.
12. Kobayashi E, Matsumoto S, Doi H, Yoneyama T, Hamanaka H. Mechanical properties of the binary titanium-zirconium alloys and their potential for biomedical materials. J Biomed Mater Res. 1995;29(8):943–50.
13. Al-Nawas B, Bragger U, Meijer HJ, Naert I, Persson R, Perucchi A, et al. A Double-Blind Randomized Controlled Trial (RCT) of Titanium-Zirconium versus Titanium Grade IV Small-Diameter Bone Level Implants in Edentulous Mandibles - Results from a 1-Year Observation Period. Clin Implant Dent Relat Res. 2012;14(6):896–904.
14. Quinney M, Al-Nawas B, Meijer HJ, Razavi A, Reichert TE, Schimmel M, et al. Small-diameter titanium Grade IV and titanium-zirconium implants in edentulous mandibles: three-year results from a double-blind, randomized controlled trial. Clin Oral Implants Res. 2014;26(7):831–40.
15. Database ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT01878331
16. Buser D, Weber HP, Lang NP. Tissue integration of non-submerged implants, 1-year results of a prospective study with 100 ITI hollow-cylinder and hollow-screw implants. Clin Oral Implants Res. 1990;1(1):33–40.
17. Bragger U. Use of radiographs in evaluating success, stability and failure in implant dentistry. Periodontol 2000. 1998;17:77–88.
18. Bragger U, Gerber C, Joss A, Haenni S, Meier A, Hashorva E, et al. Patterns of tissue remodeling after placement of ITI dental implants using an osteotomy technique: a longitudinal radiographic case study cohort. Clin Oral Implants Res. 2004;15:215–86.
19. Mombelli A, van Oosten MA, Schurch E, Lang NP. The microbiota associated with successful or failing osseointegrated titanium implants. Oral Microbiol Immunol. 1987;2(4):145–51.
20. Cho-Yan Lee J, Matthews N, Nixon KC, Ivanovski S. Residual periodontal pockets are a risk indicator for peri-implantitis in patients treated for periodontitis. Clin Oral Implants Res. 2012;23(3):325–33.
21. Karoussis IK, Kotsovitis S, Fournouiosis I. A comprehensive and critical review of dental implant diagnosis in periodontally compromised partially edentulous patients. Clin Oral Implants Res. 2007;18(6):669–79.
22. Karoussis IK, Salvi GE, Hetz-Mayfield LJ, Bragger U, Hammerle CH, Lang NP. Long-term implant prognosis in patients with and without a history of chronic periodontitis: a 10-year prospective cohort study of the ITI Dental Implant System. Clin Oral Implants Res. 2003;14(3):329–39.
23. Gujar B, Wang HY, Lang NP, Buser D. Impact of IL-1 genotype and smoking status on the prognosis of osseointegrated implants. Clin Oral Implants Res. 2004;15(4):393–400.
24. Hetz-Mayfield LJ. Peri-implant diseases: diagnosis and risk indicators. J Clin Periodontol. 2000;27(Suppl):292–304.
25. Zittmann NU, Berglund T, Marinello CP, Lindhe J. Experimental peri-implant mucositis in man. J Clin Periodontol. 2001;28(6):517–23.
26. Bassetti M, Kaufmann R, Salvi GE, Sculean A, Bassetti R. Soft tissue grafting to improve the attached mucosa at dental implants: A review of the literature and proposal of a decision tree. Quintessence Int. 2015;46(6):499–510.
27. Lin GH, Chan HL, Wang HL. The significance of keratinized mucosa on implant health: a systematic review. J Periodontol. 2013;84(12):1755–67.
28. Derks J, Hakansson J, Wenstrom K, Tomasi C, Larsson M, Berglundh T. Effectiveness of implant therapy analyzed in a Swedish population: early and late implant loss. J Dent Res. 2015;94(Suppl 4):445–51.
29. Laurell L, Lundgren D. Marginal bone level changes at dental implants after 5 years in function: a meta-analysis. Clin Implant Dent Relat Res. 2011;13(1):19–28.
30. Salvi GE, Aglietta M, Eck S, Sculean A, Lang NP, Ramsayer CA. Reversibility of experimental peri-implant mucositis compared with experimental gingivitis in humans. Clin Oral Implants Res. 2012;23(2):182–90.
31. Vogel R, Smith-Palmer J, Valentine W. Evaluating the health economic implications and cost-effectiveness of dental implants: a literature review. Int J Oral Maxillofac Implants. 2013;28(2):343–56.
32. van Kampen FM, van der Bilt A, Cune MS, Fontijn-Tekamp FA, Bosman F. Masticatory function with implant-supported overdentures. J Dent Res. 2004;83(9):708–11.
33. Müller F, Duverney E, Loup A, Vazquez L, Hermann FR, Schimmel M. Implant-supported mandibular overdentures in very old adults: a prospective randomized controlled trial. J Dent Res. 2013;92(12 Suppl):1545–50.
34. Schimmel M, Loup A, Duverney E, Gaydaron N, Müller F. The effect of lower denture abutment on masseter muscle thickness in a 97-year-old patient: a case report. Int J Prosthodont. 2010;23(4):18–20.
35. Tokmakidis SP, Kalipotharakis V, Smilios I, Parlavantzas A. Effects of detaining on muscle strength and mass after high or moderate intensity of resistance training in older adults. Clin Physiol Funct Imaging. 2009;29(4):316–9.
36. Rashid F, Awad MA, Thomason JM, Piovano A, Spielberg GP, Scilingo E, et al. The effectiveness of 2-implant overdentures - a pragmatic international multicentre study. J Oral Rehabil. 2011;38(3):176–84.
37. Awad MA, Rashid F, Feine JS, Overdenture Effectiveness Study Team C. The effect of mandibular 2-implant overdentures on oral health-related quality of life: an international multicentre study. Clin Oral Implants Res. 2014;25(1):46–51.
38. Müller F, Wahl G, Fuhr K. Age-related satisfaction with complete dentures, desire for improvement and attitudes to implant treatment. Gerodontology. 1994;11(1):7–12.
39. Steele JG, Sanders AE, Slade GD, Allen PF, Lahti S, Nuttall N, et al. How do age and tooth loss affect oral health impacts and quality of life? A study comparing two national samples. Community Dent Oral Epidemiol. 2004;32(2):107–14.
40. McGrath C, Bedi R. The importance of oral health to older people’s quality of life. Gerodontology. 1999;16(1):59–63.
41. Ozhayat EB, Gotfredsen K. Effect of treatment with fixed and removable dental prostheses. An oral health-related quality of life study. J Oral Rehabil. 2012;39(1):26–36.
42. Zhao L, Lin HC, Lo EC, Wong MC. Clinical and socio-demographic factors influencing the oral health-related quality of life of Chinese elders. Community Dent Health. 2011;28(3):206–10.
43. Walton JN, MacEntee MI. Choosing or refusing oral implants: a prospective study of edentulous volunteers for a clinical trial. Int J Prosthodont. 2005;18(6):483–8.
44. Al-Nawas B, Domagala P, Fragola G, Freiberger P, Ortiz-Vgon A, Rousseau P, et al. A prospective non-interventional study to evaluate survival and success of reduced diameter implants made from titanium-zirconium alloy. J Oral Implantol. 2014;41(4):e118–25.